Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule

Article summary

Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping the September 30 approval date on schedule.